{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:14:23Z","timestamp":1783109663679,"version":"3.54.6"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA246716"],"award-info":[{"award-number":["R01 CA246716"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13346-024-01629-3","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T20:30:06Z","timestamp":1716841806000},"page":"2203-2215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Human serum albumin-based drug-free macromolecular therapeutics induce apoptosis in chronic lymphocytic leukemia patient cells by crosslinking of CD20 and\/or CD38 receptors"],"prefix":"10.1007","volume":"14","author":[{"given":"Jiahui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Tommy","family":"Gambles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandt","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Shami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4451-6944","authenticated-orcid":false,"given":"Jind\u0159ich","family":"Kope\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"1629_CR1","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O\u2019Brien S, Gribben J, Rai K. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096. https:\/\/doi.org\/10.1038\/nrdp.2016.96.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1629_CR2","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3390\/cancers15051583","volume":"15","author":"P Iyer","year":"2023","unstructured":"Iyer P, Wang L. Emerging therapies in CLL in the era of precision medicine. Cancers. 2023;15(5):1583. https:\/\/doi.org\/10.3390\/cancers15051583.","journal-title":"Cancers"},{"issue":"7","key":"1629_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1039\/C4BM00442F","volume":"3","author":"TW Chu","year":"2015","unstructured":"Chu TW, Kope\u010dek J. Drug-free macromolecular therapeutics\u2013a new paradigm in polymeric nanomedicines. Biomaterials Sci. 2015;3(7):908\u201322. https:\/\/doi.org\/10.1039\/C4BM00442F.","journal-title":"Biomaterials Sci"},{"key":"1629_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.biomaterials.2018.10.007","volume":"190\u2013191","author":"J Yang","year":"2019","unstructured":"Yang J, Li L, Kope\u010dek J. Biorecognition: a key to drug-free macromolecular therapeutics. Biomaterials. 2019;190\u2013191:11\u201323. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.10.007.","journal-title":"Biomaterials"},{"issue":"1","key":"1629_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1021\/nn4053827","volume":"8","author":"TW Chu","year":"2014","unstructured":"Chu TW, Yang J, Zhang R, Sima M, Kope\u010dek J. Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis. ACS Nano. 2014;8(1):719\u201330. https:\/\/doi.org\/10.1021\/nn4053827.","journal-title":"ACS Nano"},{"issue":"5\u20136","key":"1629_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s13346-014-0209-8","volume":"4","author":"TW Chu","year":"2014","unstructured":"Chu TW, Kosak KM, Shami PJ, Kope\u010dek J. Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cells. Drug Deliv Transl Res. 2014;4(5\u20136):389\u201394. https:\/\/doi.org\/10.1007\/s13346-014-0209-8.","journal-title":"Drug Deliv Transl Res"},{"key":"1629_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.nano.2018.12.011","volume":"16","author":"J Wang","year":"2019","unstructured":"Wang J, Li L, Yang J, Clair PM, Glenn MJ, Stephens DM, Radford DC, Kosak KM, Deininger MW, Shami PJ, Kope\u010dek J. Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine. Nanomedicine: NBM. 2019;16:217\u201325. https:\/\/doi.org\/10.1016\/j.nano.2018.12.011.","journal-title":"Nanomedicine: NBM"},{"issue":"8","key":"1629_CR8","doi-asserted-by":"publisher","first-page":"834","DOI":"10.7150\/thno.12040","volume":"5","author":"TW Chu","year":"2015","unstructured":"Chu TW, Zhang R, Yang J, Chao MP, Shami PJ, Kope\u010dek J. A two-step pretargeted nanotherapy for CD20 crosslinking may achieve superior anti-lymphoma efficacy to Rituximab. Theranostics. 2015;5(8):834\u201346. https:\/\/doi.org\/10.7150\/thno.12040.","journal-title":"Theranostics"},{"issue":"5","key":"1629_CR9","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","volume":"18","author":"A Spada","year":"2021","unstructured":"Spada A, Emami J, Tuszynski JA, Lavasanifar A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol Pharm. 2021;18(5):1862\u201394. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00046.","journal-title":"Mol Pharm"},{"key":"1629_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2018.11.015","volume":"293","author":"L Li","year":"2019","unstructured":"Li L, Yang J, Soodvilai S, Wang J, Opanasopit P, Kope\u010dek J. Drug-free albumin-triggered sensitization of cancer cells to anticancer drugs. J Control Release. 2019;293:84\u201393. https:\/\/doi.org\/10.1016\/j.jconrel.2018.11.015.","journal-title":"J Control Release"},{"key":"1629_CR11","doi-asserted-by":"publisher","unstructured":"Gambles MT, Sborov D, Shami P, Yang J, Kope\u010dek J. Obinutuzumab-based drug-free macromolecular therapeutics synergizes with topoisomerase inhibitors. Macromol Biosci. 2023;e2300375. https:\/\/doi.org\/10.1002\/mabi.202300375.","DOI":"10.1002\/mabi.202300375"},{"key":"1629_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jconrel.2023.04.048","volume":"358","author":"MT Gambles","year":"2023","unstructured":"Gambles MT, Yang J, Kope\u010dek J. Multi-targeted immunotherapeutics to treat B cell malignancies. J Control Release. 2023;358:232\u201358. https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.048.","journal-title":"J Control Release"},{"issue":"15","key":"1629_CR13","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.3390\/molecules26154658","volume":"26","author":"MT Gambles","year":"2021","unstructured":"Gambles MT, Li J, Wang J, Sborov D, Yang J, Kope\u010dek J. Crosslinking of CD38 receptors triggers apoptosis of malignant B cells. Molecules. 2021;26(15):4658. https:\/\/doi.org\/10.3390\/molecules26154658.","journal-title":"Molecules"},{"key":"1629_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jconrel.2022.08.045","volume":"350","author":"MT Gambles","year":"2022","unstructured":"Gambles MT, Li J, Radford CD, Sborov D, Shami P, Yang J, Kope\u010dek J. Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo. J Control Release. 2022;350:584\u201399. https:\/\/doi.org\/10.1016\/j.jconrel.2022.08.045.","journal-title":"J Control Release"},{"issue":"6","key":"1629_CR15","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasov\u00e1","year":"2020","unstructured":"Pavlasov\u00e1 G, Mr\u00e1z M. The regulation and function of CD20: an enigma of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494\u2013506. https:\/\/doi.org\/10.3324\/haematol.2019.243543.","journal-title":"Haematologica"},{"issue":"13","key":"1629_CR16","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-18-3412","volume":"25","author":"A Manna","year":"2019","unstructured":"Manna A, Aulakh S, Jani P, Ahmed S, Akhtar S, Coignet M, Heckman M, Meghji Z, Bhatia K, Sharma A, Sher T, Alegria V, Malavasi F, Chini EN, Chanan-Khan A, Ailawadhi S, Paulus A. Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 2019;25(13):3974\u201385. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3412.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1629_CR17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.41608","volume":"73","author":"AD Marinov","year":"2021","unstructured":"Marinov AD, Wang H, Bastacky SI, van Puijenbroek E, Schindler T, Speziale D, Perro M, Klein C, Nickerson KM, Shlomchik MJ. The type II anti-CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine lupus model. Arthritis Rheumatol. 2021;73(5):826\u201336. https:\/\/doi.org\/10.1002\/art.41608.","journal-title":"Arthritis Rheumatol"},{"key":"1629_CR18","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","volume":"11","author":"C Zhu","year":"2020","unstructured":"Zhu C, Song Z, Wang A, Srinivasan S, Yang G, Greco R, Theilhaber J, Shehu E, Wu L, Yang ZY, Passe-Coutrin W, Fournier A, Tai YT, Anderson KC, Wiederschain D, Bahjat K, Adri\u00e1n FJ, Chiron M. Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol. 2020;11:1771. https:\/\/doi.org\/10.3389\/fimmu.2020.01771.","journal-title":"Front Immunol"},{"issue":"5","key":"1629_CR19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/cas.12918","volume":"107","author":"K Hayashi","year":"2016","unstructured":"Hayashi K, Nagasaki E, Kan S, Ito M, Kamata Y, Homma S, Aiba K. Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation. Cancer Sci. 2016;107(5):682\u20139. https:\/\/doi.org\/10.1111\/cas.12918.","journal-title":"Cancer Sci"},{"issue":"4","key":"1629_CR20","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1021\/acsnano.8b00797","volume":"12","author":"L Li","year":"2018","unstructured":"Li L, Yang J, Wang J, Kope\u010dek J. Amplification of CD20 cross-linking in rituximab-resistant B-lymphoma cells enhances apoptosis induction by drug-free macromolecular therapeutics. ACS Nano. 2018;12(4):3658\u201370. https:\/\/doi.org\/10.1021\/acsnano.8b00797.","journal-title":"ACS Nano"},{"issue":"1","key":"1629_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41375-020-0840-y","volume":"35","author":"E Garc\u00eda-Guerrero","year":"2021","unstructured":"Garc\u00eda-Guerrero E, G\u00f6tz R, Doose S, Sauer M, Rodr\u00edguez-Gil A, Nerreter T, Kort\u00fcm KM, P\u00e9rez-Sim\u00f3n JA, Einsele H, Hudecek M, Danhof S. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia. 2021;35(1):201\u201314. https:\/\/doi.org\/10.1038\/s41375-020-0840-y.","journal-title":"Leukemia"},{"issue":"8","key":"1629_CR22","doi-asserted-by":"publisher","first-page":"e16839","DOI":"10.7759\/cureus.16839","volume":"13","author":"K Khalid","year":"2021","unstructured":"Khalid K, Padda J, Syam M, Moosa A, Kakani V, Sanka S, Zubair U, Padda S, Cooper AC, Jean-Charles G. 13q14 deletion and its effect on prognosis of chronic lymphocytic leukemia. Cureus. 2021;13(8):e16839. https:\/\/doi.org\/10.7759\/cureus.16839.","journal-title":"Cureus"},{"issue":"4","key":"1629_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/cyto.b.21090","volume":"84","author":"HA Degheidy","year":"2013","unstructured":"Degheidy HA, Gadalla SM, Farooqui MZ, Abbasi F, Arthur DC, Bauer SR, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE. Bcl-2 level as a biomarker for 13q14 deletion in CLL. Cytometry B Clin Cytom. 2013;84(4):237\u201347. https:\/\/doi.org\/10.1002\/cyto.b.21090.","journal-title":"Cytometry B Clin Cytom"},{"key":"1629_CR24","doi-asserted-by":"publisher","unstructured":"Puiggros A, Blanco G, Espinet B. Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. BioMed Res Int. 2014;435983. https:\/\/doi.org\/10.1155\/2014\/435983.","DOI":"10.1155\/2014\/435983"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01629-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01629-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01629-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T14:33:20Z","timestamp":1719412400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01629-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1629"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01629-3","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"13 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave informed consent through a research protocol by the University of Utah Institutional Review Board (IRB# 45880).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approve the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.Y. and J.K. are co-inventors on US patents assigned to the University of Utah related to this work. Otherwise, the authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}